NewEdge Wealth LLC Acquires 41,166 Shares of Novartis AG $NVS

NewEdge Wealth LLC raised its stake in shares of Novartis AG (NYSE:NVS) by 8.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 546,505 shares of the company’s stock after purchasing an additional 41,166 shares during the quarter. Novartis accounts for 1.0% of NewEdge Wealth LLC’s portfolio, making the stock its 18th largest holding. NewEdge Wealth LLC’s holdings in Novartis were worth $83,479,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of NVS. Auto Owners Insurance Co raised its holdings in shares of Novartis by 13,687.0% in the 4th quarter. Auto Owners Insurance Co now owns 4,628,296 shares of the company’s stock worth $638,103,000 after buying an additional 4,594,726 shares in the last quarter. WCM Investment Management LLC bought a new position in shares of Novartis during the 1st quarter worth approximately $220,004,000. Morgan Stanley boosted its stake in Novartis by 14.9% in the 4th quarter. Morgan Stanley now owns 8,876,906 shares of the company’s stock valued at $1,223,860,000 after buying an additional 1,148,033 shares in the last quarter. GQG Partners LLC boosted its stake in Novartis by 39.6% in the 4th quarter. GQG Partners LLC now owns 3,158,122 shares of the company’s stock valued at $435,414,000 after buying an additional 895,255 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership bought a new stake in Novartis in the fourth quarter valued at $108,638,000. 13.12% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have issued reports on NVS shares. Citigroup reiterated a “buy” rating on shares of Novartis in a research note on Wednesday. Morgan Stanley upped their target price on shares of Novartis from $143.00 to $170.00 and gave the stock an “overweight” rating in a report on Thursday, March 26th. Finally, Weiss Ratings cut shares of Novartis from a “buy (a-)” rating to a “buy (b)” rating in a research report on Wednesday, April 29th. Seven investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $141.20.

Novartis Stock Performance

NYSE:NVS opened at $153.04 on Thursday. Novartis AG has a 1 year low of $112.34 and a 1 year high of $170.46. The firm has a 50 day moving average of $151.68 and a 200-day moving average of $151.99. The company has a current ratio of 0.85, a quick ratio of 0.65 and a debt-to-equity ratio of 0.96. The stock has a market capitalization of $292.02 billion, a P/E ratio of 23.08, a price-to-earnings-growth ratio of 2.66 and a beta of 0.45.

Novartis (NYSE:NVS) last released its quarterly earnings results on Tuesday, June 30th. The company reported $2.41 EPS for the quarter. The business had revenue of $14.95 billion for the quarter. Novartis had a return on equity of 38.23% and a net margin of 23.29%. As a group, sell-side analysts anticipate that Novartis AG will post 8.75 EPS for the current fiscal year.

More Novartis News

Here are the key news stories impacting Novartis this week:

• Positive Sentiment: Novartis beat Q2 estimates, reporting EPS of $2.41 versus $2.20 expected and revenue of $14.41 billion versus $14.07 billion expected, driven by strong sales in key brands and lower costs. Article Title
• Positive Sentiment: Management reaffirmed full-year 2026 guidance, which suggests the company is still confident that growth from newer drugs can outweigh declines in older products. Article Title
• Positive Sentiment: Several articles also pointed to a more constructive investor view, including a Seeking Alpha “buy thesis” upgrade and commentary that Novartis returned to sales growth as newer medicines offset generic pressure. Article Title
• Neutral Sentiment: CEO Vas Narasimhan said there is “no change of plans,” with key clinical trial readouts expected in the second half of the year. That keeps the pipeline story in focus, but it is still a waiting game. Article Title
• Negative Sentiment: Investors are still watching for headwinds from generic competition and steep sales declines in Entresto, which could limit how quickly Novartis can sustain growth. Article Title

Novartis Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.